ALK and Ehlers-Danlos syndrome, musculocontractural type: Reports have shown a case of ALK-rearranged ATC with a remarkable response to crizotinib, while NTRK-rearranged ATCs treated with larotrectinib achieved an overall response rate of 29% [49, 50].